Consensus Enliven Therapeutics, Inc.

Equities

ELVN

US29337E1029

Real-time Estimate Cboe BZX Other stock markets 20:17:45 23/05/2024 BST			5-day change	1st Jan Change
22.45 ^USD	-1.92%		-5.59%	+62.43%

05-20	Enliven Therapeutics Insider Sold Shares Worth $22,877,262, According to a Recent SEC Filing	MT
05-14	Enliven Therapeutics Q1 Loss Narrows	MT

Evolution of the average Target Price on Enliven Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

4c52fe85168ff72da76988192d.2fjKjX5oCp9FIB2s6b877amCtUnnkeU3x8MBZrSLeT4.tJCn6zEmf-oOSm34jtNcvNn4xiC0p7VnvfNOMPjdLQ6yla_LSyF-6BNHJQ~b06e99ee2bc865b2bf2b7f58cf37acd4

Analyst Recommendations on Enliven Therapeutics, Inc.

Mizuho Securities Initiates Enliven Therapeutics With Buy Rating, Price Target is $34	04-09	MT
Jefferies Initiates Enliven Therapeutics at Buy With $27 Price Target	29/03/23	MT
TD Cowen Starts Enliven Therapeutics at Outperform	03/03/23	MT